Longboard Pharmaceuticals, Inc.
4275 Executive Square, Suite 950
La Jolla, California 92037
August 9, 2023
VIA EDGAR
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attn: Joshua Gorsky
RE: Longboard Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed August 4, 2023
File No. 333-273712
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective at 4:30 p.m. Eastern Time on August 11, 2023, or as soon thereafter as is practicable.
Thank you for your assistance. If you should have any questions, please contact Steven M. Przesmicki of Cooley LLP, counsel to the registrant, at (858) 550-6070.
| LONGBOARD PHARMACEUTICALS, INC. | ||
| By: | /s/ Brandi L. Roberts | |
| Brandi L. Roberts | ||
| Chief Financial Officer | ||
